Historically, high-priority insider buys have outperformed the S&P 500 by a median ~2% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 5,751, 2021-2026). Past results don't predict the future. How we measure this ↗
Director Mason Heather L buys 75,000 shares of ASRT at $0.80; prior buy at same ticker returned +2126.8% in 30 days, +1616.5% in 90 days.
Mason Heather L purchased 75,000 shares at $0.80 on 2024-11-18, increasing her position by +35.3% to 287,650 shares total. The current price of $14.62 reflects -44.3% decline from the 52-week high of $26.25, with the stock down 16.0% over the past 30 days and 24.4% over 90 days. Her prior open-market buy at ASRT on 2024-06-05 generated exceptional returns: +2126.8% at the 30-day mark and +1616.5% at the 90-day mark, representing a 90-day win rate of 100.00% across her cross-ticker history. However, the company remains unprofitable (net income of $-2.9M on $29.2M quarterly revenue) with flat annual growth of -2.7%, and the stock is trading significantly below its 52-week highs. The repeat purchase by the same director at the same ticker—following a prior trade that showed exceptional 90-day returns—warrants examination of whether underlying fundamentals have changed or whether prior gains reflected non-fundamental drivers.
Assertio CEO O'Grady buys 11,706 shares at $0.85 as stock down 53.6% from 52-week high amid unprofitable operations.
CEO Brendan P. O'Grady purchased 11,706 shares of Assertio Holdings at $0.85 on 2024-11-14 for a total value of $9,950.49, establishing a position from zero prior holdings. The transaction occurs against a backdrop of significant stock deterioration: the current price of $12.17 is 53.6% below the 52-week high of $26.25, and the stock has declined 28.2% over the past 30 days and 29.4% over 90 days. Assertio remains unprofitable with a net loss of $2.9M in its most recent quarter, annual revenue has contracted 2.7% year-over-year, and the company operates on a $1.2B market cap. A CEO's initial purchase into equity ownership at distressed valuation levels merits investor scrutiny regarding whether this reflects conviction in a recovery thesis or simply opportunistic acquisition of shares at depressed prices during an operationally challenging period.
Add ASRT to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
